Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer

Pemetrexed-based chemotherapy (Pem-C) is the first-line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). However, limited tumor-associated proteins in blood are available to predict pemetrexed response and/or survival. Plasma samples from three responders and three nonrespo...

Full description

Saved in:
Bibliographic Details
Published inCancer management and research Vol. 13; pp. 9305 - 9318
Main Authors Li, Che-Hsing, Ko, Jiunn-Liang, Hsiao, Yu-Ping, Tsai, Ming-Hung, Lai, Yen-Chein, Hsin, I-Lun, Kang, Yu-Ting, Sheu, Gwo-Tarng, Lin, Wea-Lung, Wu, Ming-Fang
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2021
Taylor & Francis Ltd
Dove
Dove Medical Press
Subjects
biomarker
Biomarkers
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Development and progression
Dihydrofolate reductase
Disease
endoglin
Kinases
Lung cancer
Lung cancer, Non-small cell
Lung cancer, Small cell
Lymphatic system
Medical prognosis
Medical research
Medicine, Experimental
Mutation
non-squamous non-small cell lung cancer
Oncology
Original Research
Patients
Pemetrexed
pemetrexed-based therapy
Plasma
Prognosis
prognostic factor
Proteins
Taiwan
Minneapolis Minnesota
United States > US
endoglin
non-squamous non-small cell lung cancer
prognostic factor
biomarker
pemetrexed-based therapy
Online AccessGet full text

Cover

Abstract Pemetrexed-based chemotherapy (Pem-C) is the first-line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). However, limited tumor-associated proteins in blood are available to predict pemetrexed response and/or survival. Plasma samples from three responders and three nonresponders with stage IIIB-IV NSCLC were collected prior to Pem-C and analyzed using Proteome Profiler Human XL Oncology Array to detect 84 oncology-related proteins. The plasma concentrations of cathepsin S, endoglin (ENG), and matrix metalloproteinases 3 and 9 in 71 patients with advanced NSCLC treated with Pem-C were further measured using enzyme-linked immunosorbent assay based on the remarkable differences in the four proteins between responders and nonresponders in the array results. Pem-C responders had significantly higher ENG levels but not the other three markers than nonresponders (mean ENG level: 27.1 ± 7.4 vs 22.3 ± 6.9, < 0.01). High ENG concentration was correlated with improved progression-free survival (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.31-0.86, < 0.01) and overall survival (HR: 0.55, 95% CI: 0.32-0.94, < 0.05) in patients treated with Pem-C, and the ENG level was an independent factor in our cohort (HR: 0.54, 95% CI: 0.33-0.89, < 0.05). ENG concentration in Pem-C responders also significantly increased at the time of best response ( < 0.05). Cumulatively, this study reveals that ENG is correlated with Pem-C responsiveness in patients, which indicates the potential use of plasma ENG levels as a non-invasive biomarker for pemetrexed-based treatment in patients with non-squamous NSCLC.
AbstractList Purpose: Pemetrexed-based chemotherapy (Pem-C) is the first-line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). However, limited tumor-associated proteins in blood are available to predict pemetrexed response and/or survival. Patients and Methods: Plasma samples from three responders and three nonresponders with stage IIIB–IV NSCLC were collected prior to Pem-C and analyzed using Proteome ProfilerTM Human XL Oncology Array to detect 84 oncology-related proteins. The plasma concentrations of cathepsin S, endoglin (ENG), and matrix metalloproteinases 3 and 9 in 71 patients with advanced NSCLC treated with Pem-C were further measured using enzyme-linked immunosorbent assay based on the remarkable differences in the four proteins between responders and nonresponders in the array results. Results: Pem-C responders had significantly higher ENG levels but not the other three markers than nonresponders (mean ENG level: 27.1 ± 7.4 vs 22.3 ± 6.9, p < 0.01). High ENG concentration was correlated with improved progression-free survival (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.31– 0.86, p < 0.01) and overall survival (HR: 0.55, 95% CI: 0.32– 0.94, p < 0.05) in patients treated with Pem-C, and the ENG level was an independent factor in our cohort (HR: 0.54, 95% CI: 0.33– 0.89, p < 0.05). ENG concentration in Pem-C responders also significantly increased at the time of best response (p < 0.05). Conclusion: Cumulatively, this study reveals that ENG is correlated with Pem-C responsiveness in patients, which indicates the potential use of plasma ENG levels as a non-invasive biomarker for pemetrexed-based treatment in patients with non-squamous NSCLC.
Che-Hsing Li,1,2,* Jiunn-Liang Ko,1,3,4,* Yu-Ping Hsiao,5,6 Ming-Hung Tsai,7 Yen-Chein Lai,8 I-Lun Hsin,3,4 Yu-Ting Kang,3,4 Gwo-Tarng Sheu,1,3,4 Wea-Lung Lin,6,9 Ming-Fang Wu1,4,6 1Divisions of Medical Oncology and Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, 402, Taiwan; 2Graduate Program in Immunology & Microbiology, Baylor College of Medicine, Houston, TX, 77030, USA; 3Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan; 4CSMU Lung Cancer Research Center, Chung Shan Medical University, Taichung, 402, Taiwan; 5Division of Dermatology, Chung Shan Medical University Hospital, Taichung, 402, Taiwan; 6School of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan; 7Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, 40447, Taiwan; 8Department of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, 402, Taiwan; 9Department of Pathology, Chung Shan Medical University Hospital, Taichung, 402, Taiwan*These authors contributed equally to this workCorrespondence: Ming-Fang WuDivisions of Medical Oncology and Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, 110, Sec. 1, Jianguo N. Road, Taichung, 40201, TaiwanTel +886-4-24739595#34711Email mfwu0111@gmail.comPurpose: Pemetrexed-based chemotherapy (Pem-C) is the first-line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). However, limited tumor-associated proteins in blood are available to predict pemetrexed response and/or survival.Patients and Methods: Plasma samples from three responders and three nonresponders with stage IIIB–IV NSCLC were collected prior to Pem-C and analyzed using Proteome ProfilerTM Human XL Oncology Array to detect 84 oncology-related proteins. The plasma concentrations of cathepsin S, endoglin (ENG), and matrix metalloproteinases 3 and 9 in 71 patients with advanced NSCLC treated with Pem-C were further measured using enzyme-linked immunosorbent assay based on the remarkable differences in the four proteins between responders and nonresponders in the array results.Results: Pem-C responders had significantly higher ENG levels but not the other three markers than nonresponders (mean ENG level: 27.1 ± 7.4 vs 22.3 ± 6.9, p < 0.01). High ENG concentration was correlated with improved progression-free survival (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.31– 0.86, p < 0.01) and overall survival (HR: 0.55, 95% CI: 0.32– 0.94, p < 0.05) in patients treated with Pem-C, and the ENG level was an independent factor in our cohort (HR: 0.54, 95% CI: 0.33– 0.89, p < 0.05). ENG concentration in Pem-C responders also significantly increased at the time of best response (p < 0.05).Conclusion: Cumulatively, this study reveals that ENG is correlated with Pem-C responsiveness in patients, which indicates the potential use of plasma ENG levels as a non-invasive biomarker for pemetrexed-based treatment in patients with non-squamous NSCLC.Keywords: endoglin, pemetrexed-based therapy, prognostic factor, non-squamous non-small cell lung cancer, biomarker
Pemetrexed-based chemotherapy (Pem-C) is the first-line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). However, limited tumor-associated proteins in blood are available to predict pemetrexed response and/or survival.PURPOSEPemetrexed-based chemotherapy (Pem-C) is the first-line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). However, limited tumor-associated proteins in blood are available to predict pemetrexed response and/or survival.Plasma samples from three responders and three nonresponders with stage IIIB-IV NSCLC were collected prior to Pem-C and analyzed using Proteome ProfilerTM Human XL Oncology Array to detect 84 oncology-related proteins. The plasma concentrations of cathepsin S, endoglin (ENG), and matrix metalloproteinases 3 and 9 in 71 patients with advanced NSCLC treated with Pem-C were further measured using enzyme-linked immunosorbent assay based on the remarkable differences in the four proteins between responders and nonresponders in the array results.PATIENTS AND METHODSPlasma samples from three responders and three nonresponders with stage IIIB-IV NSCLC were collected prior to Pem-C and analyzed using Proteome ProfilerTM Human XL Oncology Array to detect 84 oncology-related proteins. The plasma concentrations of cathepsin S, endoglin (ENG), and matrix metalloproteinases 3 and 9 in 71 patients with advanced NSCLC treated with Pem-C were further measured using enzyme-linked immunosorbent assay based on the remarkable differences in the four proteins between responders and nonresponders in the array results.Pem-C responders had significantly higher ENG levels but not the other three markers than nonresponders (mean ENG level: 27.1 ± 7.4 vs 22.3 ± 6.9, p < 0.01). High ENG concentration was correlated with improved progression-free survival (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.31-0.86, p < 0.01) and overall survival (HR: 0.55, 95% CI: 0.32-0.94, p < 0.05) in patients treated with Pem-C, and the ENG level was an independent factor in our cohort (HR: 0.54, 95% CI: 0.33-0.89, p < 0.05). ENG concentration in Pem-C responders also significantly increased at the time of best response (p < 0.05).RESULTSPem-C responders had significantly higher ENG levels but not the other three markers than nonresponders (mean ENG level: 27.1 ± 7.4 vs 22.3 ± 6.9, p < 0.01). High ENG concentration was correlated with improved progression-free survival (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.31-0.86, p < 0.01) and overall survival (HR: 0.55, 95% CI: 0.32-0.94, p < 0.05) in patients treated with Pem-C, and the ENG level was an independent factor in our cohort (HR: 0.54, 95% CI: 0.33-0.89, p < 0.05). ENG concentration in Pem-C responders also significantly increased at the time of best response (p < 0.05).Cumulatively, this study reveals that ENG is correlated with Pem-C responsiveness in patients, which indicates the potential use of plasma ENG levels as a non-invasive biomarker for pemetrexed-based treatment in patients with non-squamous NSCLC.CONCLUSIONCumulatively, this study reveals that ENG is correlated with Pem-C responsiveness in patients, which indicates the potential use of plasma ENG levels as a non-invasive biomarker for pemetrexed-based treatment in patients with non-squamous NSCLC.
Purpose: Pemetrexed-based chemotherapy (Pem-C) is the first-line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). However, limited tumorassociated proteins in blood are available to predict pemetrexed response and/or survival. Patients and Methods: Plasma samples from three responders and three nonresponders with stage IIIB-IV NSCLC were collected prior to Pem-C and analyzed using Proteome Profler (TM) Human XL Oncology Array to detect 84 oncology-related proteins. The plasma concentrations of cathepsin S, endoglin (ENG), and matrix metalloproteinases 3 and 9 in 71 patients with advanced NSCLC treated with Pem-C were further measured using enzymelinked immunosorbent assay based on the remarkable differences in the four proteins between responders and nonresponders in the array results. Results: Pem-C responders had significantly higher ENG levels but not the other three markers than nonresponders (mean ENG level: 27.1 [+ or -] 7.4 vs 22.3 [+ or -] 6.9, p < 0.01). High ENG concentration was correlated with improved progression-free survival (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.31-0.86, p < 0.01) and overall survival (HR: 0.55, 95% CI: 0.32-0.94, p < 0.05) in patients treated with Pem-C, and the ENG level was an independent factor in our cohort (HR: 0.54, 95% CI: 0.33-0.89, p < 0.05). ENG concentration in Pem-C responders also significantly increased at the time of best response (p < 0.05). Conclusion: Cumulatively, this study reveals that ENG is correlated with Pem-C responsiveness in patients, which indicates the potential use of plasma ENG levels as a noninvasive biomarker for pemetrexed-based treatment in patients with non-squamous NSCLC. Keywords: endoglin, pemetrexed-based therapy, prognostic factor, non-squamous non-small cell lung cancer, biomarker
Pemetrexed-based chemotherapy (Pem-C) is the first-line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). However, limited tumor-associated proteins in blood are available to predict pemetrexed response and/or survival. Plasma samples from three responders and three nonresponders with stage IIIB-IV NSCLC were collected prior to Pem-C and analyzed using Proteome Profiler Human XL Oncology Array to detect 84 oncology-related proteins. The plasma concentrations of cathepsin S, endoglin (ENG), and matrix metalloproteinases 3 and 9 in 71 patients with advanced NSCLC treated with Pem-C were further measured using enzyme-linked immunosorbent assay based on the remarkable differences in the four proteins between responders and nonresponders in the array results. Pem-C responders had significantly higher ENG levels but not the other three markers than nonresponders (mean ENG level: 27.1 ± 7.4 vs 22.3 ± 6.9, < 0.01). High ENG concentration was correlated with improved progression-free survival (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.31-0.86, < 0.01) and overall survival (HR: 0.55, 95% CI: 0.32-0.94, < 0.05) in patients treated with Pem-C, and the ENG level was an independent factor in our cohort (HR: 0.54, 95% CI: 0.33-0.89, < 0.05). ENG concentration in Pem-C responders also significantly increased at the time of best response ( < 0.05). Cumulatively, this study reveals that ENG is correlated with Pem-C responsiveness in patients, which indicates the potential use of plasma ENG levels as a non-invasive biomarker for pemetrexed-based treatment in patients with non-squamous NSCLC.
Audience Academic
Author Hsiao, Yu-Ping
Lai, Yen-Chein
Lin, Wea-Lung
Li, Che-Hsing
Hsin, I-Lun
Ko, Jiunn-Liang
Sheu, Gwo-Tarng
Wu, Ming-Fang
Kang, Yu-Ting
Tsai, Ming-Hung
Author_xml – sequence: 1
  givenname: Che-Hsing
  surname: Li
  fullname: Li, Che-Hsing
– sequence: 2
  givenname: Jiunn-Liang
  surname: Ko
  fullname: Ko, Jiunn-Liang
– sequence: 3
  givenname: Yu-Ping
  surname: Hsiao
  fullname: Hsiao, Yu-Ping
– sequence: 4
  givenname: Ming-Hung
  surname: Tsai
  fullname: Tsai, Ming-Hung
– sequence: 5
  givenname: Yen-Chein
  surname: Lai
  fullname: Lai, Yen-Chein
– sequence: 6
  givenname: I-Lun
  surname: Hsin
  fullname: Hsin, I-Lun
– sequence: 7
  givenname: Yu-Ting
  surname: Kang
  fullname: Kang, Yu-Ting
– sequence: 8
  givenname: Gwo-Tarng
  surname: Sheu
  fullname: Sheu, Gwo-Tarng
– sequence: 9
  givenname: Wea-Lung
  surname: Lin
  fullname: Lin, Wea-Lung
– sequence: 10
  givenname: Ming-Fang
  orcidid: 0000-0002-7208-7067
  surname: Wu
  fullname: Wu, Ming-Fang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35221721$$D View this record in MEDLINE/PubMed
BookMark eNptkl1v0zAUhiM0xD7gjmsUiRsuaPFXHOcGqVQbTCpsYuPaOrGd1lNid3ZStn-PQztYp8lSbB0_54mO9R5nB847k2VvMZoSzMpP8--zn9MrSkVVlC-yI4zLaoIpIQePzofZcYw3CPEKU_YqO6QFIbgk-Ci7u2whdpCfOu2XrXW5jfksRq8s9Ebnv22_ys9g4wPUrckvhl75zuSND_ml6UwfzJ3Rky8QE3u9MgHW93mSzPQGnEq1H95Nrjpo23xu0mcxuGU-H6_C6-xlA200b3b7Sfbr7PR6_m2yuPh6Pp8tJqpgRT8pK86hooYbjYE2jBIgDVU1J6KsMW-oULhooDY1U6URWAlBagYIK5NAjelJdr71ag83ch1sB-FeerDyb8GHpYTQW9UaqYjigjNUa2YYbzBgjBTWrFaC6wpBcn3eutZD3RmtjOsDtHvS_RtnV3LpN1IIzishkuDDThD87WBiLzsbVXoZcMYPURJOWVFggUf0_RP0xg_BpadKFEFY8KJi_6klpAGsa3z6rxqlcsYrRBEqCUrU9BkqLW06q1KcGpvqew3vHg_6b8KH3CSAbAEVfIzBNFLZHnrrx7ltKzGSYzjlGE65C2dq-vik6cH7LP4H7qPkDw
CitedBy_id crossref_primary_10_1007_s00280_024_04734_9
crossref_primary_10_3390_curroncol31090360
Cites_doi 10.1007/s00432-014-1756-6
10.1038/s41598-019-54767-x
10.1097/JTO.0b013e3181e0b954
10.1056/NEJMoa1606774
10.1016/j.breast.2010.05.013
10.21873/anticanres.14088
10.1016/j.ejca.2016.03.081
10.1016/j.lungcan.2011.01.024
10.1016/j.cllc.2012.10.001
10.1016/j.clgc.2016.05.010
10.3390/biom10020289
10.1096/fj.201700867RR
10.1074/jbc.M111.260133
10.1038/bjc.2011.129
10.3892/ol.2013.1175
10.1007/s10637-013-9941-z
10.1634/theoncologist.2018-0299
10.1007/s13277-014-2692-4
10.1200/JCO.2012.47.1102
10.1097/JTO.0b013e31829ceba4
10.1038/bjc.2015.302
10.1158/1078-0432.CCR-18-0329
10.3389/fmed.2019.00010
10.1001/jama.2019.11058
10.1016/j.mayocp.2019.01.013
10.1016/j.lungcan.2011.10.021
10.1016/j.cllc.2015.01.003
10.1038/nrc4027
10.1016/S1470-2045(12)70063-3
10.1007/s13277-013-0842-8
10.3390/cancers12092658
10.1038/onc.2015.509
10.1515/hsz-2011-0260
10.3322/caac.21654
10.6004/jnccn.2019.0059
10.1016/j.lungcan.2010.10.012
ContentType Journal Article
Copyright 2021 Li et al.
COPYRIGHT 2021 Dove Medical Press Limited
2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 Li et al. 2021 Li et al.
Copyright_xml – notice: 2021 Li et al.
– notice: COPYRIGHT 2021 Dove Medical Press Limited
– notice: 2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 Li et al. 2021 Li et al.
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
M0S
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.2147/CMAR.S338957
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Research Library (ProQuest)
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ: Directory of Open Access Journal (DOAJ)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Research Library
ProQuest Central (New)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Li et al
EISSN 1179-1322
EndPage 9318
ExternalDocumentID oai_doaj_org_article_c2c68640bd4e46f1a110c1d4bc86d90a
PMC8866988
A690300720
35221721
10_2147_CMAR_S338957
Genre Journal Article
GeographicLocations Taiwan
Minneapolis Minnesota
United States--US
GeographicLocations_xml – name: Taiwan
– name: Minneapolis Minnesota
– name: United States--US
GrantInformation_xml – fundername: ;
GroupedDBID ---
0YH
29B
2WC
53G
5VS
7X7
8FI
8FJ
8G5
AAYXX
ABUWG
ACGFO
ADBBV
ADRAZ
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
C1A
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HMCUK
HYE
IAO
IHR
IPNFZ
ITC
KQ8
M2O
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
TDBHL
TR2
UKHRP
VDV
NPM
PMFND
3V.
7XB
8FK
K9.
MBDVC
PKEHL
PQEST
PQUKI
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c545t-7966a93e6ed1a3f432a2f3cb6287b16f38c15fabeb4c7e81c882b4a01cea2fd13
IEDL.DBID M48
ISSN 1179-1322
IngestDate Wed Aug 27 01:31:59 EDT 2025
Thu Aug 21 13:27:24 EDT 2025
Fri Jul 11 07:54:34 EDT 2025
Sun Jun 29 16:34:34 EDT 2025
Tue Jun 17 21:56:53 EDT 2025
Tue Jun 10 20:37:45 EDT 2025
Thu Jan 02 22:53:44 EST 2025
Thu Apr 24 22:54:39 EDT 2025
Tue Jul 01 02:41:32 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords endoglin
non-squamous non-small cell lung cancer
prognostic factor
biomarker
pemetrexed-based therapy
Language English
License http://creativecommons.org/licenses/by-nc/3.0
2021 Li et al.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c545t-7966a93e6ed1a3f432a2f3cb6287b16f38c15fabeb4c7e81c882b4a01cea2fd13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this work
ORCID 0000-0002-7208-7067
OpenAccessLink https://doaj.org/article/c2c68640bd4e46f1a110c1d4bc86d90a
PMID 35221721
PQID 2620186594
PQPubID 3933196
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_c2c68640bd4e46f1a110c1d4bc86d90a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8866988
proquest_miscellaneous_2634551818
proquest_journals_2620186594
gale_infotracmisc_A690300720
gale_infotracacademiconefile_A690300720
pubmed_primary_35221721
crossref_citationtrail_10_2147_CMAR_S338957
crossref_primary_10_2147_CMAR_S338957
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-01
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-01
  day: 01
PublicationDecade 2020
PublicationPlace New Zealand
PublicationPlace_xml – name: New Zealand
– name: Macclesfield
PublicationTitle Cancer management and research
PublicationTitleAlternate Cancer Manag Res
PublicationYear 2021
Publisher Dove Medical Press Limited
Taylor & Francis Ltd
Dove
Dove Medical Press
Publisher_xml – name: Dove Medical Press Limited
– name: Taylor & Francis Ltd
– name: Dove
– name: Dove Medical Press
References Tian (ref24) 2018; 32
Schoonderwoerd (ref23) 2020; 10
Paauwe (ref25) 2016; 35
Olson (ref17) 2015; 15
Wu (ref15) 2011; 72
Vidal (ref20) 2020; 40
Ettinger (ref6) 2019; 17
Wang (ref2) 2013; 8
Paz-Ares (ref9) 2013; 31
Paz-Ares (ref34) 2012; 13
Kauer (ref29) 2019; 9
Treat (ref8) 2012; 76
Hadler-Olsen (ref18) 2013; 34
Reck (ref5) 2016; 375
Apolo (ref26) 2017; 15
Avgeris (ref22) 2012; 393
Davidson (ref28) 2010; 19
Schuette (ref33) 2013; 14
Duma (ref1) 2019; 94
Jiang (ref36) 2015; 36
O’Leary (ref31) 2015; 113
Li (ref13) 2013; 5
Choueiri (ref27) 2019; 24
Okamoto (ref32) 2013; 31
Siegel (ref3) 2021; 71
Castonguay (ref35) 2011; 286
Wu (ref16) 2010; 5
Schwartz (ref21) 2016; 62
Shih (ref7) 2020; 12
Paauwe (ref30) 2018; 24
Arbour (ref4) 2019; 322
Chen (ref10) 2011; 74
Takezawa (ref11) 2011; 104
Krawczyk (ref12) 2014; 140
Rossi (ref19) 2019; 6
Park (ref14) 2015; 16
References_xml – volume: 140
  start-page: 2047
  year: 2014
  ident: ref12
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-014-1756-6
– volume: 9
  start-page: 18337
  year: 2019
  ident: ref29
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-54767-x
– volume: 5
  start-page: 1143
  year: 2010
  ident: ref16
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e3181e0b954
– volume: 375
  start-page: 1823
  year: 2016
  ident: ref5
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1606774
– volume: 19
  start-page: 493
  year: 2010
  ident: ref28
  publication-title: Breast
  doi: 10.1016/j.breast.2010.05.013
– volume: 40
  start-page: 1459
  year: 2020
  ident: ref20
  publication-title: Anticancer Res
  doi: 10.21873/anticanres.14088
– volume: 62
  start-page: 132
  year: 2016
  ident: ref21
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2016.03.081
– volume: 74
  start-page: 132
  year: 2011
  ident: ref10
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2011.01.024
– volume: 14
  start-page: 215
  year: 2013
  ident: ref33
  publication-title: Clin Lung Cancer
  doi: 10.1016/j.cllc.2012.10.001
– volume: 15
  start-page: 77
  year: 2017
  ident: ref26
  publication-title: Clin Genitourin Cancer
  doi: 10.1016/j.clgc.2016.05.010
– volume: 10
  start-page: Feb
  year: 2020
  ident: ref23
  publication-title: Biomolecules
  doi: 10.3390/biom10020289
– volume: 32
  start-page: 2934
  year: 2018
  ident: ref24
  publication-title: FASEB J
  doi: 10.1096/fj.201700867RR
– volume: 286
  start-page: 30034
  year: 2011
  ident: ref35
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M111.260133
– volume: 104
  start-page: 1594
  year: 2011
  ident: ref11
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.129
– volume: 5
  start-page: 1165
  year: 2013
  ident: ref13
  publication-title: Oncol Lett
  doi: 10.3892/ol.2013.1175
– volume: 31
  start-page: 1275
  year: 2013
  ident: ref32
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-013-9941-z
– volume: 24
  start-page: 202
  year: 2019
  ident: ref27
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2018-0299
– volume: 36
  start-page: 861
  year: 2015
  ident: ref36
  publication-title: Tumor Biol
  doi: 10.1007/s13277-014-2692-4
– volume: 31
  start-page: 2895
  year: 2013
  ident: ref9
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.47.1102
– volume: 8
  start-page: 1128
  year: 2013
  ident: ref2
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e31829ceba4
– volume: 113
  start-page: 970
  year: 2015
  ident: ref31
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2015.302
– volume: 24
  start-page: 6331
  year: 2018
  ident: ref30
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-0329
– volume: 6
  start-page: 10
  year: 2019
  ident: ref19
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2019.00010
– volume: 322
  start-page: 764
  year: 2019
  ident: ref4
  publication-title: JAMA
  doi: 10.1001/jama.2019.11058
– volume: 94
  start-page: 1623
  year: 2019
  ident: ref1
  publication-title: Mayo Clin Proc
  doi: 10.1016/j.mayocp.2019.01.013
– volume: 76
  start-page: 222
  year: 2012
  ident: ref8
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2011.10.021
– volume: 16
  start-page: e83
  year: 2015
  ident: ref14
  publication-title: Clin Lung Cancer
  doi: 10.1016/j.cllc.2015.01.003
– volume: 15
  start-page: 712
  year: 2015
  ident: ref17
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc4027
– volume: 13
  start-page: 247
  year: 2012
  ident: ref34
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(12)70063-3
– volume: 34
  start-page: 2041
  year: 2013
  ident: ref18
  publication-title: Tumor Biol
  doi: 10.1007/s13277-013-0842-8
– volume: 12
  start-page: Sep
  year: 2020
  ident: ref7
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12092658
– volume: 35
  start-page: 4069
  year: 2016
  ident: ref25
  publication-title: Oncogene
  doi: 10.1038/onc.2015.509
– volume: 393
  start-page: 301
  year: 2012
  ident: ref22
  publication-title: Biol Chem
  doi: 10.1515/hsz-2011-0260
– volume: 71
  start-page: 7
  year: 2021
  ident: ref3
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21654
– volume: 17
  start-page: 1464
  year: 2019
  ident: ref6
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2019.0059
– volume: 72
  start-page: 333
  year: 2011
  ident: ref15
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2010.10.012
SSID ssj0069134
Score 2.2022176
Snippet Pemetrexed-based chemotherapy (Pem-C) is the first-line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). However, limited...
Purpose: Pemetrexed-based chemotherapy (Pem-C) is the first-line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). However, limited...
Che-Hsing Li,1,2,* Jiunn-Liang Ko,1,3,4,* Yu-Ping Hsiao,5,6 Ming-Hung Tsai,7 Yen-Chein Lai,8 I-Lun Hsin,3,4 Yu-Ting Kang,3,4 Gwo-Tarng Sheu,1,3,4 Wea-Lung...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 9305
SubjectTerms biomarker
Biomarkers
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Development and progression
Dihydrofolate reductase
Disease
endoglin
Kinases
Lung cancer
Lung cancer, Non-small cell
Lung cancer, Small cell
Lymphatic system
Medical prognosis
Medical research
Medicine, Experimental
Mutation
non-squamous non-small cell lung cancer
Oncology
Original Research
Patients
Pemetrexed
pemetrexed-based therapy
Plasma
Prognosis
prognostic factor
Proteins
SummonAdditionalLinks – databaseName: DOAJ: Directory of Open Access Journal (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojwDBRkJxAGFxrHjOMftqqsKsaWirdRb5MekVNrNom226s9nJo_VRghx4ZJDPLFsz3jmm2TymbEPOsgKcQfE0mVZrPIqi4tQJLE1CrIgBWQt7eL8VJ9cqq9X2dXOUV9UE9bRA3cLd-hTr41WiQsKlK6ExXjlRVDOG42dttAIY96QTHU-WA_fk9HcYsq3upJ3OpPncDqf_PhyjplZQSFpJxi1nP1_euad0DQum9yJQ7Mn7HEPIPmkG_g-ewD1U_Zw3n8if8buzxAPLy0_rsPqGjEkv7nlgw4gcHrvymf2DjXvFsC_bxo0OeAIXfkZLKFZwz2E-AhjW-AXHeMAx04mfakAP13V8fnSLhZ8Cnj5hr6CT6lp_Zxdzo4vpidxf7xC7BE2NXGOmY4tJGgIwspKydSmlfROYxLlhK6k8SKrrAOnfA5GeATjTtlEeEDBIOQLtlevanjFuApgNKYq4HKnQpUbWYHOi8LmxiXS-oh9Hta59D33OB2BsSgxByGtlKSVstdKxD5upX91nBt_kTsilW1liCm7vYH2U_b2U_7LfiL2iRRe0n7GIXnb_5aAEyNmrHKiC_SDSZ4mETsYSeI-9OPmwWTK3g_clkT3L4zOChWx99tmepJq22pYbUhGKuLFEyZiLzsL206J4DEl6RHLR7Y3mvO4pb752bKEG6N1Yczr_7FIb9ijlGp52ldPB2yvWW_gLYKxxr1r991vx-wwvQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection (ProQuest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSIgXxPcCAxkJxAMKS2LHcZ5QV62aEB0T26S-Rf64jEltMvqB9udzl7qlEYKXPsSXKs6d735nX37H2DvlRY24A2Jh8zyWRZ3HpS-T2GgJuRcp5B3t4vhUnVzKL5N8EjbcFqGscuMTO0ftW0d75IdEnJ5qlZfy883PmLpG0elqaKFxl90j6jIq6Som24RL0anyutiduvEcDseD75_OMScrKRjthKGOrf9vn7wTlPoFkzsRaPSIPQzQkQ_Wun7M7kDzhN0fh8Pxp-z2DJHwzPDjxrdXiB759YJv3j54TjuufGR-oc7tFPi31RInDhxBKz-DGSzncAs-PsKo5vnFmmuA458MQpEAP22b-HxmplM-BPz5il6CD2lo_oxdjo4vhidxaKwQOwRMy7jAHMeUAhT41IhaisxktXBWYfpkU1UL7dK8NhasdAXo1CEMt9IkqQMU9Kl4zvaatoF9xqUHrTBJAVtY6etCixpUUZam0DYRxkXs4-Y9Vy6wjlPzi2mF2QdppSKtVEErEXu_lb5Zs238Q-6IVLaVIY7s7kI7v6rCkqtc5pRWMrFeglR1ahDpuNRL67RCczQR-0AKr2gl4yM5Ez5IwIkRJ1Y1UCV6wKTIkogd9CRxBbr-8MZkquABFtUfe43Y2-0w3UlVbQ20K5IRkhjxUh2xF2sL206JgDGl5xErerbXm3N_pLn-0fGDa61UqfXL_z_WK_Ygo_qcbjvpgO0t5yt4jQBrad90q-g3nPImGA
  priority: 102
  providerName: ProQuest
Title Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/35221721
https://www.proquest.com/docview/2620186594
https://www.proquest.com/docview/2634551818
https://pubmed.ncbi.nlm.nih.gov/PMC8866988
https://doaj.org/article/c2c68640bd4e46f1a110c1d4bc86d90a
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3da9swEBf9gNKXse9664IGG3sY7qxYluSHMZKQrIwlC20DeTP6OHeFxNnSZGT__U6OHWq6vvghOpvI9zvd76TzHSHvhItz5B0QxiZJQi7zJExdGoVacUhczCApyy4OR-J8wr9Nk-keqbuNVi_w9r-hne8nNVnOzja__35Bg__s05gZl596w87F2SXGWmki98kh-iTpTXTId-cJoj5fRviFPv7apsDfu_uYHHlC4sOihp8qy_nfX7TveK1mRuUdFzV4TB5V3JJ2tmB4QvageEqOhtXp-TOyGSNVnmvaL9ziGuklvbmltXrAUb8lSwf6D4LCzID-WK8QjUCR1dIxzGG1hA24sItuz9GrbTECig_pVFkEdLQowsu5ns1oD_DyHZcR2vNDy-dkMuhf9c7DqvNCaJFRrUKJQZBOYxDgmI5zHrd1O4-tERhfGSbyWFmW5NqA4VaCYhZ5uuE6YhZQ0LH4BTkoFgWcEModKIFRDBhpuMulinMQMk21VCaKtQ3Ix_o9Z7YqS-67Y8wyDE-8gjKvoKxSUEDe76R_bctxPCDX9Srbyfgi2uUPi-V1VtlkZttWKMEj4zhwkTONVMgyx41VAvGqA_LBKzzz4MO_ZHX1xQJOzBfNyjoixSUyku0oIKcNSTRR2xyuIZPVCM98JwCmRJLygLzdDfs7fdpbAYu1l4m5L5nHVEBebhG2m1IN1IDIBvYac26OFDc_ywLiSgmRKvXqwWe-Jsdtn7tTbjWdkoPVcg1vkHytTIvsy6lskcNufzS-aJVbGHj9OmWt0uL-AYbQLlM
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VVgIuiDeGAotExQGZxt71en1AKA2NUpqEqg-pN7OPcamUOiUPKH-K38hMYodECG69-OAdW96d1ze74xnGXisvCsQdEAqbJKFMiyTMfNYIjZaQeBFBMiu72Ourzon8dJqcrrFf9b8wlFZZ28SZofZDR3vk21Q4PdIqyeSHy28hdY2i09W6hcZcLPbh5w8M2cbv9z4if7fiuL173OqEVVeB0CFamIQpAnyTCVDgIyMKKWITF8JZhbGDjVQhtIuSwliw0qWgI4cY1ErTiBwgoY8EvvcG25ACQ5l1trGz2z84rG2_onPseXo99f_ZbvWah--OMArMyP0tOb5Zf4C_vcCSG1xN0Vzyee277E4FVnlzLl332BqU99nNXnUc_4BdHSD2vjB8t_TDM8Sr_HzMa36D57THy9vmO0qZHQD_PJ3gUgNHmMwP4AImI7gCH-6gH_X8eF7dgONLmlVaAu8Py_DowgwGvAV46aJd4i0aGj1kJ9ey6I_Yejks4Qnj0oNWGBaBTa30RapFASrNMpNq2xDGBextvc65q-qcU7uNQY7xDnElJ67kFVcCtrWgvpzX9_gH3Q6xbEFDVblnN4ajs7xS8tzFTmklG9ZLkKqIDGIrF3lpnVaoACZgb4jhOdkO_CRnql8gcGJUhStvqgxtbiONGwHbXKFEnXerw7XI5JXNGed_NCRgrxbD9CTl0ZUwnBKNkFSDL9IBezyXsMWUCIrThkDA0hXZW5nz6kh5_nVWkVxrpTKtn_7_s16yW53jXjfv7vX3n7HbMWUHzTazNtn6ZDSF5wjvJvZFpVOcfbluNf4N76xljQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIlVcEG8MBRaJigMyib3r9fqAUJo2amlTKtpKubn7GJdKiVPygPLX-HXMOE5IhODWiw_eseXdeX2zO55h7I3yokDcAaGwSRLKtEjCzGfN0GgJiRcRJFXZxe6R2juTn3pJb439mv8LQ2mVc5tYGWo_dLRH3qDC6ZFWSSYbRZ0WcbzT-Xj1LaQOUnTSOm-nMRORA_j5A8O38Yf9HeT1Vhx3dk_be2HdYSB0iBwmYYpg32QCFPjIiEKK2MSFcFZhHGEjVQjtoqQwFqx0KejIIR610jQjB0joI4HvvcVupyKJSMfS3iLYU3SiPUu0p05AjXa39eX9CcaDGTnCJRdYdQr42x8sOcTVZM0l79e5x-7WsJW3ZnJ2n61B-YBtdOuD-Yfs-hhR-MDw3dIPLxC58ssxn3MePKfdXt4x31HebB_45-kEFx04AmZ-DAOYjOAafLiNHtXz01mdA44vadUJCvxoWIYnA9Pv8zbg5RAtFG_T0OgRO7uRJX_M1sthCU8Zlx60wgAJbGqlL1ItClBplplU26YwLmDv5uucu7riOTXe6OcY-RBXcuJKXnMlYFsL6qtZpY9_0G0TyxY0VJ-7ujEcXeS1uucudkor2bReglRFZBBluchL67RCVTABe0sMz8mK4Cc5U_8MgROjelx5S2VofZtp3AzY5golar9bHZ6LTF5bn3H-R1cC9noxTE9SRl0JwynRCEnV-CIdsCczCVtMiUA5bQ0ELF2RvZU5r46Ul1-r2uRaK5Vp_ez_n_WKbaDy5of7RwfP2Z2Y0oSqXa1Ntj4ZTeEF4ryJfVkpFGfnN63BvwFrgmhd
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+Endoglin+is+Associated+with+Favorable+Outcome+for+Pemetrexed-Based+Therapy+in+Advanced+Non-Small+Cell+Lung+Cancer&rft.jtitle=Cancer+management+and+research&rft.au=Li%2C+Che-Hsing&rft.au=Ko%2C+Jiunn-Liang&rft.au=Hsiao%2C+Yu-Ping&rft.au=Tsai%2C+Ming-Hung&rft.date=2021-01-01&rft.issn=1179-1322&rft.eissn=1179-1322&rft.volume=13&rft.spage=9305&rft_id=info:doi/10.2147%2FCMAR.S338957&rft_id=info%3Apmid%2F35221721&rft.externalDocID=35221721
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1179-1322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1179-1322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1179-1322&client=summon